Clinical Trial Update: CAbotégravir LENacapavir DUal Long Acting [Phase 2]

View source ↗

Summary

Phase 2 trial of dual long-acting cabotegravir and lenacapavir for HIV-1 infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Apretude (cabotegravir) (cabotegravir)
• Sunlenca (lenacapavir) (lenacapavir)

Snippet

Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Conditions: HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment | Phase 2 | Status: WITHDRAWN